Table. 2.

Number of DSA and distribution of MFI to each HLA in positive vXM patients

Patient No. of DSAs ƩMFI HLA class I HLA class II CDC pXM



A B C DR DR51 DR52 DR53 DQ T cell B cell
1 7 16,331 9,448 181 5,959 43 106 47 4,430 2,527 4,178 2,343 2,853 Pos Pos
2 4 61,602 148 24,265 1,024 11,809 19,791 5,737 658 629 112 114 124 Pos Pos
3 4 28,567 10,488 8,621 4,871 4,587 185 0 0 656 182 20 9 Pos Pos
4 3 10,045 0 44 0 18 640 378 3,210 231 841 4,363 2,472 Pos Pos
5 1 23,339 1,364 1,099 649 23,339 195 271 596 926 300 Pos Pos
6 1 14,382 148 71 257 248 342 1,014 11 14,382 21 24 0 Neg Neg
7 1 4,576 128 1,317 84 247 1,464 136 342 642 505 4,576 565 Neg Neg
8 1 2,485 9 70 237 618 371 124 1,111 2,485 773 379 120 87 Neg Neg
9 1 2,445 38 76 221 209 180 193 2,445 1,231 239 134 134 Neg Neg
10 1 2,233 75 2,233 235 0 0 0 0 1 0 0 1,285 Neg Neg
11 1 2,201 126 430 1,234 1,943 257 403 352 2,201 284 383 Neg Neg
12a) 0 0 295 131 34 0 309 0 0 63 244 244 124 Pos Pos

DSA, donor-specific antibody; MFI, mean fluorescence intensity; HLA, human leukocyte antigen; vXM, virtual cross match; ƩMFI, summation of the mean fluorescence intensity values of each donor-specific antibody; CDC, complement-dependent cytotoxicity; pXM, physical cross-match; Pos, positive; Neg, negative; AR, acute rejection.

a)This patient had strong auto-antibody due to lupus, no DSA (negative vXM), positive pXM, poor compliance, mild AR (< 1 year), severe AR (>1 year), and graft loss.

Korean J Transplant 2021;35:230~237 https://doi.org/10.4285/kjt.21.0028
© Korean Journal of Transplantation